Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Department of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
Int J Mol Sci. 2024 Sep 11;25(18):9807. doi: 10.3390/ijms25189807.
Alcohol-associated liver disease (ALD) is a prevalent medical problem with limited effective treatment strategies. Although many biological processes contributing to ALD have been elucidated, a complete understanding of the underlying mechanisms is still lacking. The current study employed a proteomic approach to identify hepatic changes resulting from ethanol (EtOH) consumption and the genetic ablation of the formyl peptide receptor 2 (FPR2), a G-protein coupled receptor known to regulate multiple signaling pathways and biological processes, in a mouse model of ALD. Since previous research from our team demonstrated a notable reduction in hepatic FPR2 protein levels in patients with alcohol-associated hepatitis (AH), the proteomic changes in the livers of EtOH mice were compared to those observed in patients with AH in order to identify common hepatic proteomic alterations. Several pathways linked to exacerbated ALD in EtOH mice, as well as hepatic protein changes resembling those found in patients suffering from AH, were identified. These alterations included decreased levels of coagulation factors F2 and F9, as well as reduced hepatic levels of glutamate-cysteine ligase catalytic subunit (GCLC) and total glutathione in EtOH compared to WT EtOH mice. In conclusion, the data suggest that FPR2 may play a regulatory role in hepatic blood coagulation and the antioxidant system, both in a pre-clinical model of ALD and in human AH, however further experiments are required to validate these findings.
酒精相关性肝病(ALD)是一种普遍存在的医学问题,目前治疗策略有限。尽管许多与 ALD 相关的生物学过程已经阐明,但对其潜在机制仍缺乏全面的了解。本研究采用蛋白质组学方法,在酒精性肝病的小鼠模型中,研究了乙醇(EtOH)消耗和形式肽受体 2(FPR2)基因缺失对肝脏的影响。FPR2 是一种 G 蛋白偶联受体,已知可调节多种信号通路和生物学过程。由于我们团队之前的研究表明,酒精相关性肝炎(AH)患者肝脏中的 FPR2 蛋白水平显著降低,因此比较了 EtOH 小鼠肝脏中的蛋白质组变化与 AH 患者的观察结果,以鉴定共同的肝脏蛋白质组改变。在 EtOH 小鼠中,与加剧的 ALD 相关的几个途径以及类似于 AH 患者中发现的肝蛋白变化被鉴定出来。这些改变包括凝血因子 F2 和 F9 的水平降低,以及谷氨酸半胱氨酸连接酶催化亚基(GCLC)和总谷胱甘肽在 EtOH 中的肝水平降低,与 WT EtOH 小鼠相比。总之,数据表明 FPR2 可能在肝凝血和抗氧化系统中发挥调节作用,无论是在 ALD 的临床前模型中还是在人类 AH 中,但是需要进一步的实验来验证这些发现。